In vitro evidence suggests that trastuzumab can sensitize HER2+ breast cancer cells to radiation through the inhibition of signaling pathways involved in DNA repair mechanisms [7,27,28], although, systematic evaluations of the order of therapies and longitudinal data of cell responses are limited. Here, ERBB2 is linked to breast cancer.